Scheduling Note: The plan is for Cost Curve to be off tomorrow, back Monday. If any IRA prices leak, though, I’ll be back at it. I was kind of bummed

This has not been a great week for explanatory takes on the Inflation Reduction Act “negotiation” process. I did some whining yesterday about Reuters’ micron-deep assessment of the situation, and

So there won’t be news this week on the government’s opening offer** around price controls for the first 10 medicines selected under the Inflation Reduction Act. Companies will get the

Gird your loins, everyone.  We’re about to have the most intense 10 days in DrugPricingLand in quite some time. We’re due to have the first oral arguments over a core

The idea that hospitals are marking up prices on medicines -- not by a little, but by a whole lot -- is not a new one. PhRMA has been waving

Tyson Foods has 140,000 employees, which is a huge number of people in most contexts, but not that big a number, if we’re being honest, in the context of U.S.

I’m usually loathe to link to articles that are behind particularly high paywalls, but I’m going to make an exception. If you subscribe to BioCentury, check out this piece on

There are two weirdly similar stories out today on how to shop thoughtfully for low-priced medicines, one from USA Today and one from the Boston Globe. These two pieces are

In some ways, I’ve given up on my dream that stories about beginning-of-the-year price changes for prescription drugs will be thoughtful. Yes, it would be nice if the stories were

Lord, this is lousy.  The New York Times is out with an explainer on why the United States has high drug prices. To the extent that there are myths around